HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DL… Read more
HTG Molecular Diagnostics Inc. (HTGMQ) - Total Liabilities
Latest total liabilities as of March 2023: $10.39 Million USD
Based on the latest financial reports, HTG Molecular Diagnostics Inc. (HTGMQ) has total liabilities worth $10.39 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HTG Molecular Diagnostics Inc. - Total Liabilities Trend (2012–2022)
This chart illustrates how HTG Molecular Diagnostics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HTG Molecular Diagnostics Inc. Competitors by Total Liabilities
The table below lists competitors of HTG Molecular Diagnostics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
iExalt Inc
OTCGREY:IEXA
|
USA | $4.71 Million |
|
AGILE PROP HOLD (A8P.SG)
STU:A8P
|
Germany | €190.90 Billion |
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $5.28 Million |
|
Sabien Technology Group Plc
LSE:SNT
|
UK | GBX727.00K |
Liability Composition Analysis (2012–2022)
This chart breaks down HTG Molecular Diagnostics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 21.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.96 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HTG Molecular Diagnostics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HTG Molecular Diagnostics Inc. (2012–2022)
The table below shows the annual total liabilities of HTG Molecular Diagnostics Inc. from 2012 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $12.39 Million | -38.26% |
| 2021-12-31 | $20.06 Million | -3.15% |
| 2020-12-31 | $20.71 Million | -2.06% |
| 2019-12-31 | $21.15 Million | -6.74% |
| 2018-12-31 | $22.68 Million | -6.73% |
| 2017-12-31 | $24.32 Million | +1.12% |
| 2016-12-31 | $24.05 Million | +6.87% |
| 2015-12-31 | $22.50 Million | -31.33% |
| 2014-12-31 | $32.77 Million | +22.06% |
| 2013-12-31 | $26.85 Million | +0.58% |
| 2012-12-31 | $26.69 Million | -- |